What is Citius Oncology, Inc.'s (CTOR) StockRank?

MoatMap's StockRank for Citius Oncology, Inc. (CTOR) is 2/100, with a Strong Sell signal. This is a composite score combining Quality (21), Value (30), and Momentum (15) factor ranks across MoatMap's 20,000+ stock universe.

Does Citius Oncology, Inc. have an economic moat?

Citius Oncology, Inc. (CTOR) has a Quality factor score of 21/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Citius Oncology, Inc. a buy, hold, or sell?

MoatMap's current signal for Citius Oncology, Inc. (CTOR) is Strong Sell, based on a StockRank of 2/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Citius Oncology, Inc. in?

Citius Oncology, Inc. (CTOR) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

CTOR

STRONG SELLREMOVE

Citius Oncology, Inc. · Healthcare · United States · $65M · Avg Vol: $52K/d

StockRank

P/E (TTM)

—

ROE

-119.9%

D/E

0.1x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Citius Oncology is a late-stage oncology drug development company. It is a highly speculative, pre-revenue biotech entity with significant clinical trial and regulatory risks. It lacks the predictable cash flows, high ROIC, and established moats required by our Buffett and Smith lenses.

COMPANY DESCRIPTION

Citius Oncology, Inc. is a specialty pharmaceutical company focused on the development and commercialization of novel oncology therapeutics, including its lead asset LYMPHIR for cutaneous T-cell lymphoma. The company's competitive advantage lies in its targeted focus on late-stage, niche oncology indications with clear regulatory pathways and high unmet medical needs. It operates as a specialized developer in the oncology sector, leveraging strategic partnerships for commercialization.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	0	0	0	0	—
EPS	-0.08	-0.18	-0.31	-0.34	—
Shares	71.2M	71.2M	71.6M	83.5M	+17.2%
Debt	6.4M	22.2M	3.8M	3.8M	-16.0%
Equity	36.3M	25.5M	46.1M	44.9M	7.3%
Op CF	0	0	0.1M	-5.5M	—
Inv CF	—	0	-5.0M	-5.8M	—
Fin CF	—	0	4.9M	15.2M	—

PRICE (1Y)-24.2%

SMA 50SMA 200

$0.69

RSI (14)

34.2

52W High

$6.19

From 52W High

0.1%

SCORE BREAKDOWN

Quality

ROIC

-45.6%15.7

ROE

-119.9%6.7

GP/Assets

4.5%17.9

Op. Margin

-1716.2%5.4

FCF/Assets

-23.4%13.8

Piotroski

438.9

Int. Cover

-50.0x6.0

D/E Ratio

0.11x65.0

Current Ratio

0.50x2.3

Value

P/E (TTM)

—N/A

EV/EBITDA

—N/A

P/FCF

—N/A

P/B

1.9x61.2

P/S

11.9x23.8

Div Yield

—N/A

Momentum

52W High %

11%0.7

RS 6M

-49%23.6

SMA 50/200

0.71x5.7

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—N/A

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$65M

P/E (Forward)

—

Gross Margin

80.1%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CTOR are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
CTOR	Citius Oncology, Inc.(you)	$65M	2	STRONG SELL
JUSH.CN	Jushi Holdings Inc.	$93M	25	SELL
CWEB.TO	Charlotte's Web Holdings, Inc.	$74M	30	SELL
LFCR	Lifecore Biomedical, Inc.	$207M	10	STRONG SELL
SCYX	SCYNEXIS, Inc.	$58M	34	SELL
DERM	Journey Medical Corporation	$180M	19	STRONG SELL
AKBA	Akebia Therapeutics, Inc.	$299M	18	STRONG SELL
AQST	Aquestive Therapeutics, Inc.	$609M	11	STRONG SELL
TKNO	Alpha Teknova, Inc.	$272M	32	SELL
CL.CN	Cresco Labs Inc.	$293M	31	SELL

Peer medians: ROE -23.1% · P/E 25.2x · Gross margin 44.3%

Citius Oncology, Inc. (CTOR) — Stock Score Summary

Citius Oncology, Inc. (CTOR) has a MoatMap StockRank of 2/100 based on Quality (21/100), Value (30/100), and Momentum (15/100) factor scores. The current signal is STRONG SELL. Citius Oncology is a late-stage oncology drug development company. It is a highly speculative, pre-revenue biotech entity with significant clinical trial and regulatory risks. It lacks the predictable cash flows, high ROIC, and established moats required by our Buffett and Smith lenses.

Key Financial Metrics

Price	$0.69
Market Cap	$65M
Price/Book	1.90
Return on Equity	-119.9%
Return on Invested Capital	-45.6%
Debt/Equity	10.78
Gross Margin	80.1%
Operating Margin	-1716.2%
Free Cash Flow	$-24M

Citius Oncology, Inc. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Citius Oncology, Inc.’s (CTOR) StockRank?: MoatMap’s StockRank for Citius Oncology, Inc. (CTOR) is 2/100, with a Strong Sell signal. It is a composite of Quality (21), Value (30), and Momentum (15) factor ranks across MoatMap’s 20,000+ stock universe.
Does Citius Oncology, Inc. have an economic moat?: Citius Oncology, Inc. (CTOR) has a Quality factor score of 21/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Citius Oncology, Inc. a buy, hold, or sell?: MoatMap’s current signal for Citius Oncology, Inc. (CTOR) is Strong Sell, based on a StockRank of 2/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Citius Oncology, Inc. in?: Citius Oncology, Inc. (CTOR) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (United States).